281 research outputs found
Changes in Clinical Profile, Treatment, and Mortality in Patients Hospitalised for Acute Myocardial Infarction between 1985 and 2008
Objectives: To quantify the impact of the implementation of treatment modalities into clinical practice since 1985, on outcome of patients with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). Methods: All consecutive patients admitted for STEMI or NSTEMI at the Thoraxcenter between 1985 and 2008 were included. Baseline characteristics, pharmacological and invasive treatment modalities, and survival status were collected. The study population was categorised in three groups of patients: those hospitalised between 1985-1990, 1990-2000, and 2000-2008. Results: We identified 14,434 patients hospitalised for myocardial infarction (MI). Both STEMI and NSTEMI patients were increasingly treated with the current guideline based therapy. In STEMI, at 30 days following admission, cumulative mortality rate decreased from 17% in 1985-1990 to 13% in 1990-2000, and to 6% in 2000-2008. Adjusted 30-day and three-year mortality in the last period was 80% and 68% lower than in 1985, respectively. In NSTEMI, at 30 days following admission, cumulative mortality rate decreased from 6% in 1985-1990 to 4% in 1990-2000, and to 2% in 2000-2008. Adjusted 30-day and three-year mortality in the last period was 78% and 49% lower than in 1985, respectively. For patients admitted between 2000 and 2008, 3 year survival of STEMI and NSTEMI patients was 87% and 88%, respectively. Conclusions: Our results indicate substantial improvements in acute-and long-term survival in patients hospitalised for MI, related to improved acute-as well as long-term treatment. Early medical evaluation in suspected MI and intensive early hospital treatment both remain warranted in the future
Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes
BACKGROUND: Glycoprotein (GP) IIb/IIIa receptor blockers prevent
life-threatening cardiac complications in patients with acute coronary
syndromes without ST-segment elevation and protect against thrombotic
complications associated with percutaneous coronary interventions (PCIs).
The question arises as to whether these 2 beneficial effects are
independent and additive. METHODS AND RESULTS: We analyzed data from the
CAPTURE, PURSUIT, and PRISM-PLUS randomized trials, which studied the
effects of the GP IIb/IIIa inhibitors abciximab, eptifibatide, and
tirofiban, respectively, in acute coronary syndrome patients without
persistent ST-segment elevation, with a period of study drug infusion
before a possible PCI. During the period of pharmacological treatment,
each trial demonstrated a significant reduction in the rate of death or
nonfatal myocardial infarction in patients randomized to the GP IIb/IIIa
inhibitor compared with placebo. The 3 trials combined showed a 2.5% event
rate in this period in the GP IIb/IIIa inhibitor group (N=6125) versus
3.8% in placebo (N=6171), which implies a 34% relative reduction
(P<0.001). During study medication, a PCI was performed in 1358 patients
assigned GP IIb/IIIa inhibition and 1396 placebo patients. The event rate
during the first 48 hours after PCI was also significantly lower in the GP
IIb/IIIa inhibitor group (4. 9% versus 8.0%; 41% reduction; P<0.001). No
further benefit or rebound effect was observed beyond 48 hours after the
PCI. CONCLUSIONS: There is conclusive evidence of an early benefit of GP
IIb/IIIa inhibitors during medical treatment in patients with acute
coronary syndromes without persistent ST-segment elevation. In addition,
in patients subsequently undergoing PCI, GP IIb/IIIa inhibition protects
against myocardial damage associated with the intervention
A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure:results from an individual participant data meta-analysis of four prospective European cohorts
Background Prognostic models developed in general cohorts with a mixture of heart failure (HF) phenotypes, though more widely applicable, are also likely to yield larger prediction errors in settings where the HF phenotypes have substantially different baseline mortality rates or different predictor-outcome associations. This study sought to use individual participant data meta-analysis to develop an HF phenotype stratified model for predicting 1-year mortality in patients admitted with acute HF. Methods Four prospective European cohorts were used to develop an HF phenotype stratified model. Cox model with two rounds of backward elimination was used to derive the prognostic index. Weibull model was used to obtain the baseline hazard functions. The internal-external cross-validation (IECV) approach was used to evaluate the generalizability of the developed model in terms of discrimination and calibration. Results 3577 acute HF patients were included, of which 2368 were classified as having HF with reduced ejection fraction (EF) (HFrEF; EF &lt; 40%), 588 as having HF with midrange EF (HFmrEF; EF 40-49%), and 621 as having HF with preserved EF (HFpEF; EF &gt;= 50%). A total of 11 readily available variables built up the prognostic index. For four of these predictor variables, namely systolic blood pressure, serum creatinine, myocardial infarction, and diabetes, the effect differed across the three HF phenotypes. With a weighted IECV-adjusted AUC of 0.79 (0.74-0.83) for HFrEF, 0.74 (0.70-0.79) for HFmrEF, and 0.74 (0.71-0.77) for HFpEF, the model showed excellent discrimination. Moreover, there was a good agreement between the average observed and predicted 1-year mortality risks, especially after recalibration of the baseline mortality risks. Conclusions Our HF phenotype stratified model showed excellent generalizability across four European cohorts and may provide a useful tool in HF phenotype-specific clinical decision-making
Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events
Purpose Higher soluble ST2 (sST2) levels at admission are associated with adverse outcome in acute coronary syndrome (ACS) patients. We studied the dynamics of sST2 over time in post-ACS patients prior to a recurrent ACS or cardiac death. Methods We used the BIOMArCS case cohort, consisting of 187 patients who underwent serial blood sampling during one-year follow-up post-ACS. sST2 was batch-wise quantified after completion of follow-up in a median of 8 (IQR: 5-11) samples per patient. Joint modelling was used to investigate the association between longitudinally measured sST2 and the endpoint, adjusted for gender, GRACE risk score and history of cardiovascular diseases. Results Median age was 64 years and 79% were men. The 36 endpoint patients had systematically higher sST2 levels than those that remained endpoint free (mean value 29.6 ng/ml versus 33.7 ng/ml, p-value 0.052). The adjusted hazard ratio for the endpoint per standard deviation increase of sST2 was 1.64 (95% confidence interval: 1.09-2.34; p = 0.019) at any time point. We could not identify a steady or sudden increase of sST2 in the run-up to the combined endpoint. Conclusion Asymptomatic post-ACS patients with persistently higher sST2 levels are at higher risk of recurrent ACS or cardiac death during one-year follow-up
- …